UMVA has learned that a class of popular weight‑loss drugs might be turning the tide against several deadly cancers.
In a massive real‑world analysis of more than 12,000 patients, researchers discovered that those who began treatment with GLP‑1 medications after their cancer diagnosis experienced dramatically slower progression to advanced disease.
The study tracked individuals battling obesity‑related cancers—including lung, breast, colorectal and liver—and split them between GLP‑1 agents such as semaglutide and tirzepatide, and a comparator group taking another diabetes drug class.
Results were striking: patients on GLP‑1 therapy saw a 50% reduction in the risk of their non‑small cell lung cancers advancing, a 43% drop for breast cancer, a 31% decline for colorectal cancer, and a 38% cut for liver cancer.
Beyond halting tumor spread, the data revealed a survival edge. Tumors that expressed higher levels of GLP‑1 receptors corresponded with a roughly one‑third lower chance of death during the observation period.
Side‑effect profiles were nearly identical between the two drug groups, suggesting the cancer‑fighting benefit does not come at the cost of added toxicity.
“Our findings point to a meaningful reduction in cancer progression linked to GLP‑1 use,” said the study’s lead investigator, emphasizing that this early evidence warrants deeper exploration.
While the retrospective design cannot prove causation, the magnitude of benefit across multiple solid tumors hints that GLP‑1 pathways may directly interfere with tumor growth or metastasis.
Researchers caution that factors such as weight loss, metabolic improvements, and underlying health conditions could also play roles, and that some cancer subtypes had limited participant numbers.
Future randomized trials will be essential to confirm these observations and to unravel the biological mechanisms behind GLP‑1’s unexpected anti‑cancer effects.
